Research & Development
Abbott receives US FDA approval for Portico with FlexNav transcatheter aortic valve replacement system
21 September 2021 -

Abbott (NYSE: ABT), a global healthcare company, announced on Monday that it has received approval from the United States Food and Drug Administration (FDA) for its Portico with FlexNav transcatheter aortic valve replacement system for the treatment of people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

The company continues to provide range of structural heart solutions that include innovative, minimally invasive therapies to repair or replace diseased or damaged heart valves or close openings in the heart with the new TAVR (also referred to as TAVI, or transcatheter aortic valve implantation) advancement.

Raj Makkar, MD, associate director of Interventional Technologies at Cedars-Sinai's Smidt Heart Institute, said, 'For people in the US suffering from aortic stenosis and unable to have surgery, the Portico with FlexNav system offers a safe and effective treatment option.'

Login
Username:

Password:


Related Headlines